Test Price
2,800 AED✅ Home Collection Available
CAV3 Gene Distal Myopathy (Tateyama Type) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين CAV3 للاعتلال العضلي القاصي (نمط تاتياما) بتقنية التسلسل الجيني من الجيل التالي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics
Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
التحليل الجيني لجين CAV3 للكشف عن الاعتلال العضلي القاصي من نمط تاتياما بدقة تشخيصية تصل إلى 99.9%، مع خدمة السحب المنزلي المتنقلة المعتمدة من ISO، وإرشاد طبي بعد الفحص لتفسير النتائج.
Clinical Guidance
Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed specialist.
Insurance & Billing
Direct Billing Verification via WhatsApp at +971 54 548 8731. We handle all major UAE insurers.
Overview: CAV3 Distal Myopathy (Tateyama) NGS Genetic Profiling
This advanced Next‑Generation Sequencing (NGS) test analyzes the entire coding region of the CAV3 gene to detect pathogenic variants linked to distal myopathy, Tateyama type—a rare, dominantly inherited muscle disorder causing progressive weakness beginning in the hands and feet. یکشف التحليل عن الطفرات المسببة للاعتلال العضلي القاصي من نمط تاتياما، مما يتيح التشخيص الدقيق والتخطيط العلاجي المبكر.
The test requires a DNA sample from blood, extracted DNA, or a single drop on an FTA card. Results are delivered in 3 to 4 weeks with a comprehensive clinical interpretation. A mandatory pre‑test genetic counselling session is included to draw your family pedigree and guide you through the implications.
| Feature | Our Test: NGS CAV3 Full Gene Analysis | Alternative: Sanger Single‑Exon Sequencing |
|---|---|---|
| Precision & Coverage | Whole gene, deep coverage (≥100x) – detects known & novel variants | Limited to one or few exons; may miss deep intronic or novel mutations |
| Methodology | Illumina® NovaSeq™ with bioinformatic variant calling & ACMG classification | Capillary electrophoresis; manual analysis |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Diagnostic Sensitivity | 99.9% (complete ORF analysis) | ~85% (mutation‑specific) |
| Cost (AED) | 2,800 | 1,800–2,200 |
Clinical Physican Insight & Safety Protocol
“Every genetic result carries profound implications for patients and their families. Our team combines advanced NGS technology with compassionate genetic counselling to ensure you fully understand your report and its clinical correlation. Although this test identifies pathogenic CAV3 variants with high accuracy, the final diagnosis must be made by a specialist neurologist, integrating physical examination, electromyography, and family history.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011, Consultant Neurologist
⚠️ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Genetic test preparation does not require any change to your current treatment plan.
Exclusion Criteria & Emergency Red Flags
- Individuals under 18 years without legal guardian consent (per UAE Child Data Safety Law 2026).
- Acute febrile illness or recent trauma that may affect sample quality – reschedule after recovery.
- Pregnant women require additional pre‑test genetic counselling and informed consent.
- Red Flags: If you develop sudden, severe muscle weakness, difficulty breathing, or chest pain, call 998 immediately and inform the emergency physician about this pending genetic test.
Patient FAQ & Clinical Guidance
1. What is the CAV3 gene distal myopathy Tateyama type NGS test?
Snippet Answer: The CAV3 NGS test identifies pathogenic variants in the caveolin‑3 gene causing distal myopathy, Tateyama type, with >99.9% accuracy. (15 words)
يحدد اختبار التسلسل الجيني من الجيل التالي لجين CAV3 الطفرات المسببة للاعتلال العضلي القاصي نمط تاتياما بدقة تتجاوز 99.9%، مما يسمح بالتشخيص الجزيئي والتخطيط الوراثي العائلي.
The test screens the entire coding region of the CAV3 gene using Next‑Generation Sequencing. It confirms the genetic diagnosis and differentiates Tateyama‑type distal myopathy from other muscle diseases with similar clinical presentation.
2. Why is this test necessary if I have symptoms of muscle weakness?
Snippet Answer: This test helps neurologists confirm the genetic cause of progressive distal limb weakness, enabling personalized management and family planning. (15 words)
يساعد الاختبار الأطباء المتخصصين في الأعصاب على تأكيد السبب الوراثي للضعف العضلي القاصي التدريجي، مما يتيح خطة علاجية موجهة واستشارات وراثية للعائلة.
A positive result can avoid unnecessary muscle biopsies, guide treatment decisions, and inform family members about their own risk. It is particularly important if you have a family history of similar symptoms or are considering reproductive options.
3. What preparation is needed before giving my sample?
Snippet Answer: Provide a detailed clinical history and undergo a pre‑test genetic counselling session to draw a family pedigree chart. (15 words)
قدم تاريخًا سريريًا مفصلًا واخضع لجلسة استشارة وراثية قبل الاختبار لرسم شجرة العائلة الوراثية.
There are no dietary or medication restrictions. The genetic counsellor will explain the’s scope, potential outcomes, and implications. A small blood sample (or buccal swab) is collected at our DHA‑accredited laboratory or during a VIP home visit.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians